The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies

Xin Lu¹, Guochun Wang², Qinglin Peng³, Kai Yuan⁴ and Hanbo Yang⁵, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, ²Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ⁵Rheumatology, China-Japan Friendship Hospital, Beijing, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Calcinosis and juvenile dermatomyositis, Idiopathic Inflammatory Myopathies (IIM)

Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM).

Methods: Sera from 198 Chinese patients with IIM including 15 Juvenile dermatomyositis(JDM), 133 dermatomyositis(DM) and 50 polymyositis(PM), other connective tissue diseases(CTD) including 70 systemic lupus erythematosus(SLE), 60 rheumatoid arthritis(RA), 25 systemic sclerosis(SSc), 46 primary Sjogren’s syndrome(PSS), 10 mixed connective tissue disease(MCTD) and 60 healthy controls were measured by enzyme linked immunosorbent assay. The positive sera were further examined by immunoprecipitation assay. We analyzed the distribution of these autoantibodies in each groups and evaluated the association between autoantibodies and clinical features of IIM.

Results: The positive rate of anti-NXP-2 autoantibodies in IIM patients was 5%, patients with JDM 20%, DM 3.7% and PM 4%, respectively. The positive rate of anti-NXP-2 autoantibodies were statistical differences within JDM, DM and PM groups(P=0.043). There was no positive for the antibodies from patients with other CTD as well as healthy controls. Anti-NXP-2-positive patients had significantly younger age compared with anti-NXP-2-negative patients(t=-2.09,P<0.05). The incidence of calcinosis in the anti-NXP2-positive patients was significantly higher than that in the negative patients(P<0.01).There were no statistical differences between positive and negative groups for gender, duration, arthritis, rash, dysphagia, myalgia, myasthenia, Raynaud’s phenomenon, interstitial lung disease and concomitant with cancer(P>0.05). In laboratory examination, the sera levels of aspartate aminotransferase, IgA, complement C3 were significantly increased in anti-NXP-2-positive patients than those in anti-NXP-2-negative patients(P<0.05). However, there was no significantly statistical differences between two groups for sera levels of creatine kinase, lactate dehydrogenase, hydroxybutyrate dehydrogenase, alanine aminotransferase, γ-glutamyltranspeptidase, erythrocyte sedimentation rate, C-reactive Protein and the positive rate of tumor markers(P>0.05). Among the three anti-NXP-2-positive JDM patients, two patients showed calcinosis and myasthenia, one of them who died 10 months later had increasing level of anti-NXP-2 autoantidodies, severe myasthenia and rapid progress.

Conclusion: This study first reported the sera levels of anti-NXP-2 autoantibodies in Chinese patients with IIM and other CTD. We found that anti-NXP-2 autoantibodies only exist in patients with IIM. Anti-NXP-2 autoantibodies were associated with young-onset IIM and calcinosis.

Disclosure:

X. Lu,
None;

G. Wang,
None;

Q. Peng,
None;

K. Yuan,
None;

H. Yang,
None.

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-and-clinical-usefulness-of-anti-nxp-2-autoantibodies-in-chinese-patients-with-idiopathic-inflammatory-myopathies/